<DOC>
	<DOCNO>NCT00458458</DOCNO>
	<brief_summary>( A ) Major 1 ) compare effectiveness norethindrone acetate ( NA ) GnRH agonist ( Lupron-Depot-3 ) relieve symptoms endometriosis , 2 ) compare bone density two treat group order demonstrate NA affect bone density ; ( B ) Minor : 1 ) To compare lipid profile patient two group confirm hypothesis effect NA GnRH agonists lipid profile similar , 2 ) To determine whether quality life , assessed questionnaire , good patient assign NA patient assign GnRH , 3 ) To determine whether NA few adverse effect GnRH agonist .</brief_summary>
	<brief_title>Treatment Endometriosis With Norethindrone Acetate ( NA ) VS. Gonadotropin- Releasing Hormone ( GnRH ) Agonist ( Lupron Depot 11.25 mg )</brief_title>
	<detailed_description>Objectives : ( A ) Major 1 ) compare effectiveness norethindrone acetate ( NA ) GnRH agonist ( Lupron-Depot-3 ) relieve symptoms endometriosis , 2 ) compare bone density two treat group order demonstrate NA affect bone density ; ( B ) Minor : 1 ) To compare lipid profile patient two group confirm hypothesis effect NA GnRH agonists lipid profile similar , 2 ) To determine whether quality life , assessed questionnaire , good patient assign NA patient assign GnRH , 3 ) To determine whether NA few adverse effect GnRH agonist . After sign IRB approve consent 112 woman symptomatic endometriosis , diagnose surgically , treat NA Lupron-Depot-3 24 week . After 24 week group treat NA 52 week . After , group follow additional 52 week assess return clinical symptom determine whether laboratory test drug relate change return pretreatment level . Treatment regimens follow : For first 24 week , woman NA group treat 5 mg NA daily placebo injection every 12 week . In case bleeding , NA dose increase ( max 15 mg ) bleeding stop , decrease 2.5 mg every 4 week final dose 7.5 mg maintain remainder 24 week . For first 24 week , woman GnRH group receive Lupron-Depot-3 injection every 12 week plus placebo pill daily - bleeding treated increase placebo pill simulate treatment NA group . After 24 week , woman identical regimen 5 mg NA pill daily injection . On first treatment day , subject follow tests/assessments : bone density DEXA , score endometriosis symptom , quality life questionnaire , general physical examination , lipid profile , estradiol ( E2 ) , N-telopeptide , pregnancy test . All test , except bone density lipid profile , repeat 12 , 24 , 52 week treatment . Bone density perform 24 52 week lipid profile perform 12 52 week treatment . In follow-up period , physical examination , quality life questionnaire , score symptom do 3 , 6 , 9 12 month . Lipid profile , N-telopeptide E2 perform 3 12 month bone density 12 month follow-up . The objective state compare two group 12 , 24 , 52 week treatment 6-month interval follow-up period .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Dyspareunia</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<criteria>The subject voluntarily sign Informed Consent form content fully explain , question answer prior undergoing studyrelated procedure . The subject premenopausal female least 18 year age time screen regular period ( 2142 day interval ) menopausal symptom . The subject diagnosis endometriosis make via laparoscopy laparotomy ( operative report obtain ) still symptomatic least 3 month surgery grade 2 accord Biberoglu 's pain grade screen visit ( 4 week prior initiation treatment ) 4 10 visual pain scale ( visual analogue ) Subject good health , except endometriosis , mild medical condition stable control . The subject clinically relevant hepatic , renal , cardiovascular , respiratory , endocrine , metabolic , psychiatric , neurologic ( epilepsy ) , hematolytic ( coagulopathy ) and/or immunologic disease ( steroid ) disorder . A subject receive hormone therapy ( GnRH agonist danazol progestin ) must meet minimum washout requirement eligible . ( GnRH within last 6 month steroid within last month . ) After hormonal therapy stop , subject must return normal least two menstrual cycle baseline time . Serum pregnancy urine qualitative pregnancy test perform screen baseline must negative . Unless surgical sterile bilateral tubal ligation vasectomy partner , subject agrees use doublebarrier method contraception screen period , throughout 24week treatment period , : condom plus spermicide , diaphragm plus spermicide , sponge plus spermicide , abstinence acceptable form birth control . Less grade III overweight BMI &lt; 40 kg/M2 Less 3 month postpartum postlactation time dose . Abnormal laboratory finding consider clinically significant twice normal range . Abnormal test repeat , still high state , subject exclude . A previous history significant adverse reaction hormone , progestin progesterone GnRH agonist therapy . Abnormal Pap smear last 6 month . Subjects ASCUS ( atypical squamous cell undetermined significance ) negative highrisk human papilloma virus ( HPV ) eligible . Subjects atypical endocervical cell , atypical glandular cell eligible study . Subject bone density T score less equal 2.5 , history nontraumatic fracture , history spinal surgery , history fusion lumbar region , history severe scoliosis great 20 degree .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>Dysmenorrhea</keyword>
	<keyword>Pelvic Pain</keyword>
	<keyword>Period Pain</keyword>
	<keyword>Menstrual Cramps</keyword>
	<keyword>Dyspareunia</keyword>
	<keyword>Norethindrone Acetate</keyword>
	<keyword>Lupron Depot</keyword>
	<keyword>Bone Density</keyword>
	<keyword>Lipid Profile</keyword>
</DOC>